Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1173 Results

Intervention Indication Therapeutic Area Year Actions
Ublituximab (TG-1101) in combination with umbralisib (TGR-1202) for chronic lymphocytic leukaemia Ublituximab (TG-1101; LFB-R603) , Umbralisib (TGR-1202; RP-5264) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2017 View  |  Download
Ublituximab for treating multiple sclerosis Ublituximab (TG-1101; LFB-R603) Multiple sclerosis (MS) Neurology 2022 View  |  Download
Ublituximab in Combination with Ibrutinib for High Risk Chronic Lymphocytic Leukaemia Ibrutinib (Imbruvica) , Ublituximab (TG-1101; LFB-R603) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2018 View  |  Download
Udenafil for congenital heart disease in adolescents after fontan palliation Udenafil (Zydena; DA8159; ME-3113; WC-3043; WC-3055) Congenital heart disease Cardiovascular System 2018 View  |  Download
Upadacitinib for active psoriatic arthritis with inadequate response to biological or non-biological DMARDs Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Psoriatic arthritis Dermatology , Rheumatology 2019 View  |  Download
Upadacitinib for Adults with Moderate to Severe Active Rheumatoid Arthritis After Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs) or Biologic DMARDs Failure Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Rheumatoid arthritis Rheumatology 2017 View  |  Download
Upadacitinib for Ankylosing Spondylitis Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Ankylosing spondylitis Musculoskeletal System 2020 View  |  Download
Upadacitinib for atopic dermatitis Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Atopic dermatitis Dermatology 2019 View  |  Download
Upadacitinib for moderate to severe active Crohn’s disease Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Crohn's disease Gastroenterology , Immunology 2021 View  |  Download
Upadacitinib for non-radiographic axial spondyloarthritis Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Axial spondyloarthritis Rheumatology 2021 View  |  Download
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications